newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific